> Details

Buergy, Daniel; Würschmidt, Florian; Gkika, Eleni; Hörner‐Rieber, Juliane; Knippen, Stefan; Gerum, Sabine; Balermpas, Panagiotis; Henkenberens, Christoph; Voglhuber, Theresa; Kornhuber, Christine; Barczyk, Steffen; Röper, Barbara; Rashid, Ali; Blanck, Oliver; Wittig, Andrea; Herold, Hans‐Ulrich; Brunner, Thomas B.; Klement, Rainer J.; Kahl, Klaus Henning; Ciernik, Ilja F.; Ottinger, Annette; Izaguirre, Victor; Putz, Florian; König, Laila; [...]

Stereotactic or conformal radiotherapy for adrenal metastases: Patient characteristics and outcomes in a multicenter analysis

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Stereotactic or conformal radiotherapy for adrenal metastases: Patient characteristics and outcomes in a multicenter analysis
  • Contributor: Buergy, Daniel; Würschmidt, Florian; Gkika, Eleni; Hörner‐Rieber, Juliane; Knippen, Stefan; Gerum, Sabine; Balermpas, Panagiotis; Henkenberens, Christoph; Voglhuber, Theresa; Kornhuber, Christine; Barczyk, Steffen; Röper, Barbara; Rashid, Ali; Blanck, Oliver; Wittig, Andrea; Herold, Hans‐Ulrich; Brunner, Thomas B.; Klement, Rainer J.; Kahl, Klaus Henning; Ciernik, Ilja F.; Ottinger, Annette; Izaguirre, Victor; Putz, Florian; König, Laila; [...]
  • Published: Wiley, 2021
  • Published in: International Journal of Cancer, 149 (2021) 2, Seite 358-370
  • Language: English
  • DOI: 10.1002/ijc.33546
  • ISSN: 0020-7136; 1097-0215
  • Origination:
  • Footnote:
  • Description: <jats:title>Abstract</jats:title><jats:p>To report outcome (freedom from local progression [FFLP], overall survival [OS] and toxicity) after stereotactic, palliative or highly conformal fractionated (&gt;12) radiotherapy (SBRT, Pall‐RT, 3DCRT/IMRT) for adrenal metastases in a retrospective multicenter cohort within the framework of the German Society for Radiation Oncology (DEGRO). Adrenal metastases treated with SBRT (≤12 fractions, biologically effective dose [BED10] ≥ 50 Gy), 3DCRT/IMRT (&gt;12 fractions, BED10 ≥ 50 Gy) or Pall‐RT (BED10 &lt; 50 Gy) were eligible for this analysis. In addition to unadjusted FFLP (Kaplan‐Meier/log‐rank), we calculated the competing‐risk‐adjusted local recurrence rate (CRA‐LRR). Three hundred twenty‐six patients with 366 metastases were included by 21 centers (median follow‐up: 11.7 months). Treatment was SBRT, 3DCRT/IMRT and Pall‐RT in 260, 27 and 79 cases, respectively. Most frequent primary tumors were non‐small‐cell lung cancer (NSCLC; 52.5%), SCLC (16.3%) and melanoma (6.7%). Unadjusted FFLP was higher after SBRT vs Pall‐RT (<jats:italic>P</jats:italic> = .026) while numerical differences in CRA‐LRR between groups did not reach statistical significance (1‐year CRA‐LRR: 13.8%, 17.4% and 27.7%). OS was longer after SBRT vs other groups (<jats:italic>P</jats:italic> &lt; .05) and increased in patients with locally controlled metastases in a landmark analysis (<jats:italic>P</jats:italic> &lt; .0001). Toxicity was mostly mild; notably, four cases of adrenal insufficiency occurred, two of which were likely caused by immunotherapy or tumor progression. Radiotherapy for adrenal metastases was associated with a mild toxicity profile in all groups and a favorable 1‐year CRA‐LRR after SBRT or 3DCRT/IMRT. One‐year FFLP was associated with longer OS. Dose‐response analyses for the dataset are underway.</jats:p>
  • Access State: Open Access